Screener
First Tracks Biotherapeutics Inc TRAX Total Operating Expenses
Total Operating Expenses at other companies
Where this comes from
Reported directly by First Tracks Biotherapeutics Inc in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: First Tracks Biotherapeutics Inc’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:32 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-224190
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $33,955 | $41,465 |
| General and administrative | 18,856 | 9,815 |
| Total operating expenses | 52,811 | 51,280 |
| Loss from operations | (52,811) | (51,280) |
| Other income (expense), net: | ||
| Interest income | 2,328 | 4,091 |
| Other expense, net | (1) | (7) |
Item 1. Combined Financial Statements.
FAQ
- What is First Tracks Biotherapeutics Inc's total operating expenses?
- First Tracks Biotherapeutics Inc (TRAX) reported total operating expenses of $52.81M in Q1 2026.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.
Ask your AI about First Tracks Biotherapeutics Inc's total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude